ARTICLE | Finance
Highlights of weekly biotech stock moves
Regulatory, clinical and other milestones
May 5, 2014 7:00 AM UTC
Acorda Therapeutics Inc. (NASDAQ:ACOR) fell $3.51 (10%) to $32.39 on Friday after FDA asked for an additional clinical trial in a complete response letter for Plumiaz diazepam nasal spray to treat acute repetitive seizures in epileptics.
Acorda was off $1.07 on the week...